{"changeSha256":"460dc2c0b015feb90841da8c2a4f7ccec16ab7567bf0236fce086b1e3c178d6f","changedAt":"2026-07-29","changedFields":[{"after":"A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.","before":"A mitochondrial-derived peptide included in an FDA compounding-risk record.","field":"Profile summary"},{"after":"FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.","before":"FDA's compounding-risk page says it has not identified human exposure data for drug products containing MOTS-c and lacks important safety information.","field":"Evidence note"},{"after":"fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026","before":"fda-bulk-peptide-risks","field":"Cited source records"},{"after":"U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026]","before":"U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]","field":"Named organizations"},{"after":"name: fda-mots-c-briefing; aliases: fda-mots-c-briefing; category: fda-bulk-peptide-risks, fda-mots-c-briefing; status: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; summary: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026","before":"name: fda-bulk-peptide-risks; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/mots-c/versions/2/","version":2},"id":"profile:mots-c:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review.","peptideSlugs":["mots-c"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/mots-c/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-mots-c-briefing","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA briefing document for MOTS-c","url":"https://www.fda.gov/media/193347/download","verifiedAt":"2026-07-29"},{"id":"fda-pcac-peptide-meeting-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting","url":"https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026","verifiedAt":"2026-07-29"}],"subject":{"slug":"mots-c","type":"profile"}}